Filing Details

Accession Number:
0001181431-10-035798
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-07-02 13:00:00
Reporting Period:
2010-06-30
Filing Date:
2010-07-02
Accepted Time:
2010-07-02 12:58:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1061027 Sunesis Pharmaceuticals Inc SNSS Pharmaceutical Preparations (2834) 943295878
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1277631 Forest Baskett 1954 Greenspring Drive
Suite 600
Timonium MD 21093
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-06-30 23,824,451 $0.28 23,824,451 No 4 P Indirect See Note 1
Common Stock Acquisiton 2010-06-30 9,994,990 $0.00 33,819,441 No 4 C Indirect See Note 1
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Note 1
No 4 C Indirect See Note 1
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2010-06-30 999,499 $0.00 9,994,990 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. The Reporting Person is a manager of NEA 12 GP, LLC, the sole general partner of NEA Partners 12, Limited Partnership ("NEA Partners 12"). NEA Partners 12 is the sole general partner of New Enterprise Associates 12, Limited Partnership ("NEA 12"). NEA 12 is the sole member of Growth Equity Opportunities Fund, LLC ("GEO"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "1934 Act"), or otherwise of such portion of the securities of the issuer held by GEO in which the Reporting Person has no pecuniary interest therein.
  2. Each one (1) share of Series A Preferred Stock was converted into ten (10) shares of Common Stock upon the issuer's common equity closing (as defined in the applicable Certificate of Designation). The Series A Perferred Stock had no expiration date.